Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis

NCT00646399 is registered in ClinicalTrials.gov with Biosynexus Incorporated as lead sponsor.

NCT NCT00646399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00646399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis
Lead sponsor
Biosynexus Incorporated
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2009
Completion date
May 31, 2011
Enrollment
1,579 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcal sepsis